Interview with Alberto Grua, Managing Director, Grunenthal Italy
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
With the objective of reinforcing and expanding basic and clinical research on T1D, in late 2007 a specialized and independent research Institute – denominated Diabetes Research Institute (DRI) – was launched at San Raffaele. DRI is part of the International DRI federation (DRI-NET), which includes 12 other DRI’s around the world. The San Raffaele DRI is composed of six Units of Basic Research and five Groups of Clinical Research.
The overall objective of DRI is to prevent and cure T1D. To achieve this objective, two specific programs are pursued, both of which take advantage of patients and animal models:
Contact
San Raffaele Hospital – Milan, via Olgettina 60, 20132 Milan, Italy
Tel. 02 26 431
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
Intermediate distribution plays a crucial role in establishing bridges between industrial production and final delivery to patients- and in Italy, this function is executed with highly contained costs and commercial…
You have led a successful career within the Solvay Group in various European countries. Looking back at all these international assignments, including you current function of regional Director South Europe,…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
After long experience in the pharmaceutical industry, working in both multinational and local laboratories, you took the reins of the already well-established Italian subsidiary of Ferring a few months ago.…
See our Cookie Privacy Policy Here